Increased prelaminar tissue thickness in patients with open-angle glaucoma and type 2 diabetes

Yoon Seop Sim¹, Jin-Woo Kwon¹, Donghyun Jee¹*, Jin A. Choi¹*, Seung-Hyun Ko², Chan Kee Park³

¹ Department of Ophthalmology and Visual Science, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ² Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea, ³ Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

* jinah616@catholic.ac.kr (JAC); donghyunjee@catholic.ac.kr (DJ)

Abstract

Background
The characteristics of the optic nerve head (ONH) in open angle glaucoma (OAG) patients with diabetes have not been reported. This study aimed to characterize the ONH structures and glaucomatous damage in diabetic OAG patients, using age-matched non-diabetic OAG patients and control subjects.

Methods
The locations of visual field defects of OAG patients were classified and the prelaminar thickness and lamina cribrosa depth were measured in 64 OAG patients with type 2 diabetes (OAG+DM), 68 OAG patients without diabetes (OAG-DM), and 36 controls. All participants were scanned by spectral domain-optical coherence tomography. The anterior prelaminar depth and lamina cribrosa depth were measured at the center of the reference line (the Bruch’s membrane opening plane). The prelaminar tissue thickness was obtained by subtracting the anterior prelaminar depth from the anterior lamina cribrosa depth.

Results
The visual field defects in the OAG+DM group were more commonly found in the inferior hemifield ($P = 0.010$), and tended to involve the central visual field compared to the OAG-DM group ($P = 0.044$). In the comparison of ONH parameters, the prelaminar thickness was highest in the OAG+DM group, followed by the control subjects and the OAG-DM group ($P = 0.035$). Post-hoc testing showed that prelaminar thickness was significantly greater in the OAG+DM group than in the OAG-DM group ($P = 0.033$). The lamina cribrosa depth was deepest in the OAG+DM group, followed by the OAG-DM group and the control subjects ($P = 0.006$).
Conclusions

Diabetic and non-diabetic OAG patients exhibit different characteristics of glaucoma, particularly increased prelaminar thickening in diabetics.

Introduction

Diabetes is associated with many ocular complications. Although diabetic retinopathy (DR) is the most well-known complication of diabetes, patients with diabetes may have other ocular complications such as cataract, corneal disease, glaucoma and optic disc abnormalities such as anterior ischemic optic neuropathy, and diabetic papillopathy.[1]

In recently published meta-analyses, diabetes increased the prevalence of glaucoma with a relative risk of 1.48.[2] Neurovascular coupling is impaired in the early stages of DR, and neurodegeneration of the optic nerve occurs even before the onset of clinically detectable DR.[3, 4] However, except for neovascular glaucoma caused directly by diabetes, the relationship between diabetes and glaucoma is still not completely known. The Rotterdam Eye Study reported that the presence of diabetes was not associated with open-angle glaucoma (OAG).[5] The ocular hypertension treatment study reached a similar conclusion, with the presence of diabetes protecting against the development of OAG, with a hazard ratio of 0.40 (0.18–0.92).[6]

However, diabetes is significantly associated with increased intraocular pressure (IOP).[2, 7] In recently published meta-analyses, the presence of diabetes was associated with an increase of IOP of 0.18 mmHg, and with an increase in 10 mg/dl in fasting glucose was 0.09 mmHg.[2] Although the association between diabetes and IOP is weak, the results are consistent throughout the population–based studies. A high glucose level in aqueous humor of patients with diabetes may accelerate the depletion of trabecular meshwork cells by accumulation of fibronectin in trabecular meshwork.[8] The aqueous level of transforming growth factor-β2 is particularly high in glaucoma patients with diabetes, compared to those without it.[9, 10]

In subjects with diabetes, functional changes and thinning of the inner retina due to neural degeneration have been reported, even before clinically visible retinal changes occur.[11, 12] And this inner retina thinning occurs especially on the superior side of the optic nerve head (ONH), which is clearly different from those resulting from glaucomatous RNFL damage, which occurs predominantly in the inferior temporal side of ONH.[13, 14] In addition, biomechanical properties of the ONH are affected by diabetes, including increased stiffness,[15] and advanced glycation end products accumulate in the ONH in diabetics.[16] These findings suggest that the ONH may exhibit different characteristics between diabetic and non-diabetic patients. However, the characteristics of the ONH in OAG patients with diabetes have not been reported. In the present study, we characterized the structure of the ONH and glaucomatous damage in type 2 diabetic OAG patients, using age-matched non-diabetic OAG patients and control subjects. Our research focused only on subjects with type 2 diabetes, because type 1 and 2 diabetes have a difference in pathogenesis.

Materials and methods

Study subjects

In this cross-sectional retrospective study, OAG patients with type 2 diabetes (OAG+DM), age-matched OAG patients without diabetes (OAG-DM), and non-diabetic, non-glaucomatous controls, all of whom had visited the Glaucoma Clinic of St. Vincent’s Hospital at Catholic University of Korea, and underwent enhanced depth imaging spectral-domain optical imaging.
coherence tomography (OCT) of the optic nerve head between July 2014 and July 2015, were included. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Institutional Review Board of St. Vincent’s Hospital, the Catholic university, College of Medicine (VC14RISI0153), which waived the written informed consent because of the study’s retrospective design.

Study subjects underwent a review of their medical history and a full ophthalmic evaluation including the following: a best-corrected visual acuity measurement, slit-lamp biomicroscopy, gonioscopy, Goldmann applanation tonometry, a dilated fundus examination, optic disc and red-free retinal nerve fiber layer (RNFL) photography using a digital fundus camera (CF-60UD; Canon, Tokyo, Japan), Cirrus HD- OCT (Carl Zeiss Meditec, Dublin, CA, USA), and standard automated perimetry 24–2 (Swedish Interactive Threshold Algorithm standard program, Humphrey Visual Field Analyzer; Carl Zeiss Meditec). Patients with at least 2 years of follow-up comprising more than three visual field tests were chosen.

All subjects were required to have a BCVA of 20/40 or better, a with a spherical refraction of -8.0 to +3.0 diopters (D), cylinder correction within ±3.0 D, and clear ocular media, and a normal anterior chamber angle. Participants with the following were excluded: neurological diseases that could affect the visual field (VF) results, a history of ocular surgery other than cataract extraction, or eyes yielding consistently unreliable VF results (defined as >25% false-negative results, >25% false-positive results, or >20% fixation losses).

Glaucoma was defined by the presence of glaucomatous optic neuropathy associated with typical reproducible VF defects evident on standard automated perimetry. A glaucomatous VF change was defined as a glaucoma hemifield test result outside normal limits and the presence of at least three contiguous points in the pattern deviation plot with values of P < 5%, with at least one point associated with a value of P < 1% (excluding points directly above or below the blind spot), on two consecutive reliable standard automated perimetry examinations.

Diabetes was diagnosed in subjects with a fasting plasma glucose ≥ 126 mg/dL or with symptoms of diabetes plus casual plasma glucose concentrations of ≥ 200 mg/dL, based on the 1997 and 2003 revisions of the American Diabetes Association guidelines.[17] DR was graded by retinal specialists (D.-H.J. and J.-W.K) assigned to each eye according to the modified Airlie House classification system. DR, if present, was categorized into five categories, following the international clinical DR severity scales: non-diabetic retinopathy (equivalent to the Early Treatment Diabetic Retinopathy Study [ETDRS] scale level 10), mild non-proliferative diabetic retinopathy (NPDR; equivalent to ETDRS 20), moderate NPDR (equivalent to ETDRS 35, 43, and 47), severe NPDR (equivalent to ETDRS 53A–53E), and proliferative diabetic retinopathy (PDR) (equivalent to ETDRS ≥ 61).[18] We excluded eyes with type 1 diabetes, PDR or neovascular glaucoma, the presence of diabetic macular edema, or any other retinal disease. Patients with interventions such as panretinal photocoagulation and intravitreal injection were also excluded.

The control group had a normal optic disc appearance upon examination of color stereoscopic photographs (an intact neuroretinal rim without peripapillary hemorrhage, thinning, or localized pallor), an IOP ≤ 21 mmHg, the absence of any RNFL abnormality visible on red-free fundus photographs, and normal VF test results. A normal VF presentation was defined as a glaucoma hemifield test result within normal limits, with mean and pattern standard deviation values associated with probabilities of normality > 5%.

**Classification of VF defects**

The VF defects of OAG patients were classified according to the pattern standard deviation, as described by Keltner et al.[19] First, the defects were classified into three groups involving the
superior, inferior, or both hemifields. Then they were classified into two groups including patients with and without involvement of the central 10˚ of the VF.[20, 21] The VF defect was classified independently in random order and in a blinded manner, without knowledge of the clinical information, by 2 of the authors (J.-A.C., and Y.-S.S).

**Optical coherence tomography protocols and analyses**

Imaging with spectral domain optical coherence tomography (SD-OCT) (Cirrus high-definition OCT, Carl Zeiss Meditec) was performed after ≥6mm pupil dilation with a 0.5% solution of phenylephrine hydrochloride and 0.5% tropicamide. The Cirrus SD-OCT automatically detected the center of the disc and then drew a circumpapillary circle from the cube dataset for RNFL thickness analyses, using the built-in analysis algorithm. The average and clock-hour peripapillary RNFL thicknesses and the ONH parameters (disc area, rim area, and vertical cup-to-disc ratio) were recorded. In addition, a horizontal section running through the center of the ONH and fovea was scanned using a 1 HD line scan (9 mm length). The HD line scans were performed in enhanced depth imaging mode, as described in a previous study.[22] All measurements were performed using ImageJ software (National Institutes of Health, Bethesda, Maryland, USA). The anterior prelaminar depth was determined by measuring the distance from the Bruch’s membrane opening plane to the level of the anterior surface of the prelaminar tissue, and the anterior lamina cribrosa depth was defined as the distance from the Bruch’s membrane opening plane to the level of anterior surface of the lamina cribrosa (Fig 1). The distance from the reference line to the level of the anterior surface of the prelaminar tissue and anterior and posterior surface of the lamina cribrosa were measured at three points: the maximally depressed point and two additional points (100 µm and 200 µm from the maximally depressed point in the temporal direction).[23, 24] For each patient, the mean of three values was used. The prelaminar tissue thickness was obtained by subtracting the anterior prelaminar depth from the anterior lamina cribrosa depth (Fig 1C). In 31 of the 168 patients (18.4%), the posterior borders of the lamina cribrosa were not clear enough to be identified.

![Fig 1. An optical coherence tomography optic nerve head image for measurement of the anterior lamina depth and prelaminar thickness.](https://doi.org/10.1371/journal.pone.0211641.g001)
Subfoveal choroidal thickness was defined as the vertical distance from the hyperreflective line of Bruch’s membrane to the hyperreflective line of the inner surface of the sclera. The thicknesses of the choroid at regions 1.5 mm nasal and temporal to the fovea were also examined, and the average value of three measurements was defined as the average macula choroidal thickness. All images were reviewed by two of the investigators (YSS, CJA). To evaluate the interobserver reproducibility of our measuring method, 15 randomly selected SD-OCT data-sets were evaluated by 2 investigators and the intraclass correlation coefficient (ICC) was calculated. Images with a signal strength < 6, obvious motion or blinking artifacts, or poor-quality enhanced depth imaging OCT images were excluded.

Data analyses
The data were analyzed using SPSS statistical software for Windows, version 16 (SPSS, Chicago, IL, USA). The data were tested for normal distribution using the Shapiro-Wilk test. One-way analysis of variance with a Bonferroni post hoc test was used to compare the clinical characteristics of OAG patients with or without type 2 diabetes and control subjects. Categorical parameters in baseline characteristics and the distribution of VF defects in each group were compared using the χ² test. For the multiple comparisons, a Bonferroni correction was applied. To determine factors associated with the prelaminar tissue thickness in OAG patients, multivariate linear regression analyses were used. The dependent variable was the prelaminar tissue thickness. For multiple linear regression analyses, variables with P < 0.15 (presence of type 2 DM, disc area, and mean deviation) in univariate analyses were included in the multivariate model. A value of P < 0.05 was considered statistically significant.

Results
A total of 333 patients with diabetes received an ophthalmic examination between July 2014 and July 2015. Among them, 134 patients having normal optic disc with or without RNFL defect were excluded. Among them, 80 were excluded due to absence of glaucomatous VF defect, 30 were excluded due to presence of PDR or macula edema, and 25 were excluded because of poor EDI images. Finally, 64 OAG+DM patients, 68 age-matched OAG-DM patients, and 36 healthy control subjects were included in this study. There were no statistically significant differences in age, SE, IOP, and central corneal thickness (CCT) among the groups (P = 0.806, 0.486, 0.185, and 0.275, respectively). The average duration of diabetes in the OAG+DM group was 11.3 ± 8.2 years. The OAG+DM group included 39 (60.9%) patients with no DR, 16 (25.0%) with mild NPDR, and 9 (14.1%) with moderate NPDR. No patients in this group had PDR. The interobserver ICC for measuring the prelaminar tissue thickness, laminar cribrosa depth and laminar cribrosa thickness were 0.894 (95% confidence interval (CI): 0.725, 0.959), 0.827 (95% CI, 0.573, 0.930), and 0.873 (95% CI, 0.670, 0.951), respectively. And the intraobserver ICC for measuring the prelaminar tissue thickness, laminar cribrosa depth and laminar cribrosa thickness were 0.910 (95% CI, 0.846, 0.948), 0.995 (95% CI, 0.993, 0.996), and 0.962 (95% CI, 0.934, 0.978), respectively.

Mean deviation and average RNFL thicknesses measured using OCT were significantly different among the groups (both, P < 0.001, Table 1). In post hoc tests, the control group had significantly higher mean deviation and average RNFL thicknesses than the OAG+DM and OAG-DM groups (both, P < 0.001). However, there were no significant differences in either measurement between the OAG+DM and OAG-DM groups (both, P > 0.999).

Table 2 shows the differences in the locations of VF defects in OAG patients with or without DM. There were 46 (71.9%) and 47 (69.1%) isolated hemifield defects in the OAG+DM and OAG-DM groups, respectively (P = 0.849; χ² test). The defects in the OAG+DM group were
## Table 1. Demographics of open angle glaucoma patients and age-matched control subjects.

|                          | OAG with type 2 diabetes | OAG without type 2 diabetes | Age-matched controls | P value | Post hoc testing |
|--------------------------|--------------------------|-----------------------------|----------------------|---------|------------------|
|                          | n = 64                   | n = 68                      | n = 36               |         |                  |
| Age, years               | 59.4 ±12.3 (35–81)       | 59.4 ± 13.2 (33–80)         | 57.9 ± 9.4 (43–70)   | 0.806   |                  |
| Spherical Equivalent, D  | -1.08 ± 2.18 (-7.0–+1.88)| -0.71 ± 2.13 (-7.88–+2.63) | -1.30 ± 0.51 (-7.88–+2.60) | 0.486   |                  |
| CCT, μm                  | 556.3 ± 32.6 (454–614)   | 544.1 ± 47.3 (453–654)      | 551.5 ± 30.9 (485–596)| 0.275   |                  |
| IOP, mmHg                | 14.5 ± 3.5 (8–26)        | 13.5 ± 3.7 (8–22)           | 13.4 ± 3.0 (8–20)    | 0.185   |                  |
| Lens status              |                          |                             |                      |         |                  |
| No cataract, n (%)       | 41 (64.1%)               | 45 (66.2%)                  | 23 (63.9%)           | 0.895   |                  |
| Mild cataract, n (%)     | 16 (25.0%)               | 13 (19.1%)                  | 9 (25.0%)            |         |                  |
| Pseudophakia, n (%)      | 7 (10.9%)                | 10 (14.7%)                  | 4 (11.1%)            |         |                  |
| Anti-glaucoma medication |                          |                             |                      |         |                  |
| PGA, n (%)               | 23 (35.9)                | 42 (61.7)                   | NA                   | 0.003   |                  |
| Beta-blocker, n (%)      | 37 (57.8)                | 39 (57.3)                   | NA                   | 0.549   |                  |
| Topical carbonic anhydrase inhibitor, n (%) | 23 (35.9) | 26 (38.2) | NA | 0.463 |                  |
| Alpha-agonist, n (%)     | 17 (26.6)                | 15 (22.1)                   | NA                   | 0.344   |                  |
| Pilocarpine, n (%)       | 1 (1.5)                  | 1 (1.5)                     | NA                   | 0.737   |                  |
| Total no. of anti-glaucoma medication | NA | 0 (0) | NA | 0.001 |                  |
|                          | 5 (7.8)                  | 49 (72.1)                   | NA                   |         |                  |
| ≥2                       | 5 (7.8)                  | 19 (27.9)                   | NA                   |         |                  |
| Mean deviation, dB       | -4.3 ± 3.9 (-20.93–+0.22) | -5.1 ± 3.2 (-13.81–+0.04)  | -0.8 ± 1.4 (-3.01–+2.56) | <0.001 | OAG+DM<C, OAG-DM<C |
| Disc area, mm²            | 2.19 ± 0.57 (0.64–3.58)  | 2.10 ± 0.42 (1.12–3.21)     | 2.10 ± 0.42 (1.36–3.22) | 0.477   |                  |
| Rim area, mm²            | 0.95 ± 0.23 (0.46–1.47)  | 0.95 ± 0.27 (0.52–2.37)     | 1.20 ± 0.26 (0.70–1.83) | <0.001 | OAG+DM<C, OAG-DM<C |
| Vertical cup-to disc ratio| 0.72 ± 0.08 (0.45–0.86)  | 0.74 ± 0.10 (0.46–0.92)     | 0.58 ± 0.15 (0.40–0.83) | <0.001 | OAG+DM<C, OAG-DM<C |
| Average RNFL thickness, μm| 78.8 ± 12.0 (50–107)     | 77.9 ± 11.5 (54–106)        | 92.7 ± 9.2 (76–115)   | <0.001 | OAG+DM<C, OAG-DM<C |

OAG, open-angle glaucoma; D, diopters; IOP, intraocular pressure; CCT, central corneal thickness; PGA, prostaglandin analogue, RNFL, retinal nerve fiber layer.

https://doi.org/10.1371/journal.pone.0211641.t001

## Table 2. Location of visual field defect in open angle glaucoma patients with or without type 2 diabetes.

|                          | OAG with type 2 diabetes | OAG without type 2 diabetes | P value |
|--------------------------|--------------------------|-----------------------------|---------|
| According to the vertical location of scotoma |                      |                             |         |
| Superior, n (%)          | 18 (28.1)                | 33 (48.5)                   | 0.010*  |
| Inferior, n (%)          | 28 (41.2)                | 14 (20.6)                   |         |
| Both, n (%)              | 18 (28.1)                | 21 (30.9)                   |         |
| According to the involvement of central visual field |                      |                             |         |
| With central visual field involvement, n (%) | 29 (45.3) | 20 (29.4) |         |
| Without central visual field involvement, n (%) | 35 (54.7) | 48 (70.6) |         |

OAG, open-angle glaucoma.

* Bonferroni-adjusted P = 0.03

https://doi.org/10.1371/journal.pone.0211641.t002
most commonly found in the inferior hemifield, whereas those in the OAG-DM group tended to occur in the superior hemifield (Bonferroni-adjusted \( P = 0.030; \chi^2 \) test). In addition, the OAG+DM group tended to involve the central VF (\( P = 0.044; \chi^2 \) test).

In comparisons of the clock-hour RNFL thicknesses between OAG patients with or without DM, the OAG+DM group tended to have a relatively thinner RNFL on the superior side of the ONH (\( P = 0.016 \) at the 3 o’clock side), whereas the OAG-DM group showed a relatively thinner RNFL on the inferior side (\( P < 0.001, 0.027 \) at the 7 and 8 o’clock sides, respectively; Fig 2).

Among the groups, the prelaminar tissue thickness was highest in the OAG+DM group, followed by the control subjects and the OAG-DM group (\( P = 0.035; \) Table 3). In post hoc tests, the prelaminar tissue thickness was significantly higher in the OAG+DM group than in the OAG-DM group (\( P = 0.033 \)). Among OAG patients, there was gradual prelaminar thickening in the order of the OAG-DM patients, the OAG+DM patients without DR, and the OAG+DM patients with DR (\( P = 0.010, \) Fig 3). In post hoc tests, the OAG+DM patients with DR had significantly higher prelaminar tissue than the OAG-DM patients (\( P = 0.015 \)). The lamina cribrosa depth was deepest in the OAG+DM group followed by the OAG-DM group and controls (\( P = 0.006 \)), being significantly deeper than that in controls (\( P = 0.007 \)) but without significance between the other groups (\( P = 0.074 \)). No significant differences were noted in the lamina cribrosa thickness (\( P = 0.507 \)). Macular choroidal thickness was significantly thinner in the OAG+DM group and OAG-DM group compared with controls (\( P < 0.001 \)). In both univariate and multivariate analyses, the presence of DM was a significant factor affecting the prelaminar tissue thickness in OAG patients (Table 4).

![Fig 2. Clock-hour-based retinal nerve fiber layer thicknesses in open-angle glaucoma patients with or without type 2 diabetes and normal controls.](https://doi.org/10.1371/journal.pone.0211641.g002)
Discussion

OAG patients with type 2 diabetes tended to have a glaucomatous VF defect in the inferior hemifield, and glaucomatous RNFL damage at the superior side of the ONH (Tables 2 and 3). Our results are consistent with previous studies that have found that OAG patients with inferior VF defects have a significantly higher frequency of diabetes[26] and vice versa.[27]

RNFL loss, which is common in patients with diabetes as a manifestation of non-glaucomatous diabetic optic neuropathy, occurs predominantly in the superior hemisphere.[13, 14, 28, 29] This is usually related to vascular insufficiency associated with diabetes, which is the key pathogenic mechanism of DR.[12, 29, 30] However, the key pathogenic feature of glaucoma is mechanical deformation of the lamina cribrosa, such as posterior displacement, thinning, and compression of the lamina cribrosa, and the inferior temporal side of the lamina cribrosa is more susceptible to damage from nerve fibers that pass through the region (Fig 2; Table 2). Posterior displacement of the lamina cribrosa and the resultant deepening of the lamina cribrosa are important structural parameters of glaucomatous changes, because they occur mostly

Table 3. Optic nerve head parameters and macular choroidal thickness in open angle glaucoma patients with or without type 2 diabetes and age-matched controls.

| ONH parameters | OAG with type 2 diabetes | OAG without type 2 diabetes | Age-matched controls | \( P \) value | Post hoc testing |
|----------------|-------------------------|-----------------------------|---------------------|-------------|----------------|
| Prelaminar thickness, \( \mu m \) | 115.3 ± 51.9 | 89.4 ± 38.6 | 105.2 ± 68.5 | 0.035 | With vs without DM | With DM vs. control | Without DM vs. control |
| Anterior lamina depth, \( \mu m \) | 790.3 ± 163.6 | 714.8 ± 169.4 | 657.6 ± 168.6 | 0.006 | 0.074 | 0.007 | 0.477 |
| Lamina cribrosa thickness, \( \mu m \) | 226.8 ±73.2 | 235.7 ± 72.0 | 249.3 ± 61.6 | 0.507 | 0.999 | 0.748 | 0.999 |
| Macular choroidal thickness | | | | | |
| Subfoveal choroidal thickness, \( \mu m \) | 103.0 ± 24.5 | 98.4 ± 23.1 | 247.6 ± 56.9 | <0.001 | 0.999 | <0.001 | <0.001 |
| Temporal macular choroidal thickness, \( \mu m \) | 90.9 ± 18.0 | 85.8 ± 17.5 | 255.0 ± 58.5 | <0.001 | 0.999 | <0.001 | <0.001 |
| Nasal side macular choroidal thickness, \( \mu m \) | 85.0 ± 17.9 | 85.8 ± 22.0 | 242.9 ± 54.3 | <0.001 | 0.999 | <0.001 | <0.001 |

DM, diabetes mellitus; ONH, optic nerve head

https://doi.org/10.1371/journal.pone.0211641.t003

Fig 3. Comparison of the prelaminar thickness among open-angle glaucoma patients. Among open angle glaucoma (OAG) patients, there were gradual prelaminar thickening in the order of the OAG+DM patients, the OAG+DM patients without diabetic retinopathy (DR), and the OAG+DM patients with DR (\( P = 0.010 \)) In post hoc testing, the OAG+DM patients with DR had significantly higher thicker prelaminar tissue than the OAG+DM patients (\( P = 0.015 \)).

https://doi.org/10.1371/journal.pone.0211641.g003
in very early-stage glaucoma,[31] and ONH surface changes have been shown to precede changes in the RNFL.[32] Notably, both diabetic and non-diabetic OAG patients had deeper lamina cribrosa than control subjects. However, they also exhibited a different pattern of glaucomatous damage from non-diabetic OAG patients, although they were both accompanied by a comparable degree of mechanical deformation. Lee et al. reported that changes in retinal capillary blood flow were more closely related to ONH morphology in diabetic OAG patients than in non-diabetic OAG patients, which suggests that retinal blood flow insufficiency plays a larger role in glaucomatous ONH progression in diabetics’ eyes.[33] Taken together, these findings suggest that additional pathogenic factors may play a role in the pathogenesis of OAG in patients with diabetes.

The prelaminar tissue is located just above the lamina cribrosa, and is composed of neuronal and glial tissue. With the progression of glaucoma, the thicknesses of the prelaminar tissue and lamina cribrosa decrease.[24, 34] However, unlike the lamina cribrosa, the prelaminar tissue is characterized by its plasticity, and quickly responds to changes in IOP. A rise in IOP results in compression of the prelaminar tissue,[35] which then thickens after surgical IOP reduction.[36]

Consistent with previous studies, in our study, the thickness of the prelaminar tissue was lowest in non-diabetic OAG patients (Table 3).[34] However, we found paradoxical thickening of the prelaminar tissue in eyes with diabetic OAG. Such thickening can be caused by an increased glial reaction, connective tissue remodeling, or blockage of axonal transport,[37] considering that there were no difference in macular choroidal thickness between diabetic and non-diabetic OAG patients (Table 3). In diabetes, the biomechanical properties of the ONH are altered. Terai et al.[15] reported that increased stiffness was noted in the ONH and peripapillary sclera in animal models, which could be caused by an accumulation of advanced end products and high glucose levels in diabetic patients.[16] Retrograde axonal transport is also impaired in the ONH of rats with streptozotocin-induced diabetes.[38, 39] This sclerotic change in the ONH in diabetes may affect the axonal transport and result in the thickening of the prelaminar tissue. In addition, in diabetes, hyperglycemia and inflammation affect retinal glial cells, resulting in increased glial reactivation, particularly in the early course of the disease.[40] In the future, a longitudinal study is required to determine the significance of the role of prelaminar tissue thickening on the progression of glaucoma in diabetic patients.

In our study, the laminar depth was deepest in the diabetic OAG patients, followed by the non-diabetic OAG patients and the controls (Table 3). However, Yokota et al. who compared the structure of the lamina cribrosa between eyes with and without neovascular glaucoma, reported that the depth and thickness of the lamina cribrosa were not different. It is inferred that the effects of IOP on the structure of lamina cribrosa depends on the nature of IOP.

| Parameters                     | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
| Presence of type 2 diabetes   | 27.39 (8.91, 45.86) | 20.19 (63.58, 36.81) |
| Age                           | 0.39 (-0.33, -1.12) | 0.284                 |
| Disc area                     | 11.35 (-7.14, 29.84)| 0.226                 |
| Spherical equivalent          | -2.16 (-6.48, 2.14) | 0.321                 |
| CCT                           | 0.10 (-0.15, 0.36)  | 0.415                 |
| Average RNFL thickness        | -0.53 (-1.31, 0.25) | 0.180                 |

CI, confidence interval; CCT, central corneal thickness; RNFL, retinal nerve fiber layer.
elevation. Short-term IOP elevation did not evoke significant changes in the structure of the lamina cribrosa.\[41\] Beotra et al. also found that subjects with angle closure glaucoma experience lower strains in lamina cribrosa than those with open angle glaucoma.\[42\] In addition, there was no statistically significant difference in the lamina depth between non-diabetic OAG patients and the controls on post-hoc testing (Table 3). This result seems to be associated with the relatively high proportion of normal tension glaucoma in Korean population, occupying 77% of the open angle glaucoma.\[43\] Li et al. has shown that the lamina cribrosa is more posteriorly located in high tension glaucoma than normal tension glaucoma, and the parameter does not have a good level of diagnostic accuracy for detecting normal tension glaucoma.\[44\] Furthermore, the IOP was highest in diabetic OAG patients, followed by non-diabetic OAG patients in our study. Akkaya et al.\[45\] showed that diabetic patients without glaucoma showed thicker and more anteriorly positioned lamina cribrosa compared with those for healthy controls, suggesting that the neuroprotective effect of diabetes is related with those structural characteristics. In the ocular hypertension treatment study,\[6\] diabetes exhibited protective effects on the development of glaucoma. However, in advanced glaucoma intervention study,\[46\] diabetes was shown to be one of the risk factors for glaucoma progression. In this regards, it seems that the effects of diabetes on the ONH are different according to the stage of glaucoma. Further studies on the transition of laminar position and thickness according to glaucoma progression in diabetic patients are necessary.

The pattern of the VF impacts vision-related quality of life. A superior hemifield defect is strongly associated with difficulty with near activity, whereas an inferior hemifield defect impacts vision-specific role difficulties and general and peripheral vision.\[47\] Clusters in the inferior paracentral VF of healthy eyes are particularly strongly associated with the quality of life.\[48\] In the present study, OAG patients with diabetes tended to have an inferior VF defect. As their diabetes progressed, they were likely to receive further interventions, such as panretinal photocoagulation or intravitreal injection, which additionally affected their visual functions. Therefore, personalized advice should be provided to OAG patients with diabetes, accompanied by a more detailed medical history review in these patients.

There were some potential limitations in this study. First, we excluded eyes with PDR or neovascular glaucoma, because the reliability of OCT images for these disorders was low. Thus, OAG patients with advanced DR may have different characteristics than shown in this study. Second, the results should be interpreted in the context of the study design. A major limitation is the retrospective nature of data collection. In addition, this study is clinically based and did not use population-based screening. Third, we measured only the central three points in each B-scan, which precisely showed the structural characteristics of the lamina cribrosa, and we only measured the prelaminar tissue thickness and lamina cribrosa depth among other ONH parameters, because the precise measurement of ONH was not the primary goal of our study. In addition, the lateral magnification was not accounted for in the OCT imaging in this study. The lateral magnification may affect the measurement in lamina cribrosa configuration, especially in case of large eyeballs. Although all subjects were required to have a limited range of spherical refraction and cylinder correction in this study, this could influence the results, considering the wide range of refractive errors and hence axial lengths included. The main aim of this study is to investigate the ONH characteristics in glaucoma patients with diabetes. Regarding the comparison of VF defect patterns between groups, we chose the post-hoc tests, instead of the planned contrasts. Because this is a post hoc exploratory finding, the results must be interpreted in light of the restrictions inherent in the study design. Finally, conditions such as lens opacities could have affected the enhanced depth imaging images, particularly in patients with diabetes, so we discarded cases with poor enhanced depth imaging OCT images and utilized Cirrus OCT scans with signal strengths ≥ 6.
In summary, diabetic OAG patients exhibited different characteristics of glaucoma than non-diabetic OAG patients. Importantly, significant thickening of the prelaminar tissue was found in diabetic OAG patients. Overall, our results indicate that the pathogenic mechanism of glaucoma may be altered by diabetes, and thus OAG patients with diabetes need to be customized in clinical practice.

Supporting information
S1 Table. Baseline and structural data in open-angle glaucoma patients with or without type 2 diabetes and normal controls. (XLS)

Author Contributions
Conceptualization: Jin A. Choi, Chan Kee Park.
Investigation: Jin A. Choi, Seung-Hyun Ko.
Methodology: Jin A. Choi, Seung-Hyun Ko.
Resources: Jin-Woo Kwon, Donghyun Jee, Seung-Hyun Ko.
Writing – original draft: Yoon Seop Sim, Jin A. Choi.
Writing – review & editing: Jin A. Choi.

References
1. Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes care. 2008; 31(9):1905–12. Epub 2008/08/30. https://doi.org/10.2337/dc08-0342 PMID: 18753669; PubMed Central PMCID: PMCPmc2518369.
2. Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015; 122(1):72–8. Epub 2014/10/07. https://doi.org/10.1016/j.ophtha.2014.07.051 PMID: 25283061.
3. Lasta M, Pemp B, Schmidl D, Boltz A, Kaya S, Palkovits S, et al. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Investigative ophthalmology & visual science. 2013; 54(1):842–7. Epub 2013/01/12. https://doi.org/10.1167/iovs.12-10873 PMID: 23307962.
4. Tavares Ferreira J, Alves M, Dias-Santos A, Costa L, Santos BO, Cunha JP, et al. Retinal Neurodegeneration in Diabetic Patients Without Diabetic Retinopathy. Investigative ophthalmology & visual science. 2016; 57(14):6455–60. Epub 2016/11/29. https://doi.org/10.1167/iovs.16-20215 PMID: 27893887.
5. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Witterman JC, Hofman A, et al. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology. 2006; 113(10):1827–31. Epub 2006/08/04. https://doi.org/10.1016/j.ophtha.2006.03.063 PMID: 16884777.
6. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of ophthalmology (Chicago, Ill: 1960). 2002; 120(6):714–20; discussion 829–30. Epub 2002/06/07. PMID: 12049575.
7. Cohen E, Kramer M, Shochat T, Goldberg E, Krause I. Relationship Between Serum Glucose Levels and Intraocular Pressure, a Population-based Cross-sectional Study. Journal of glaucoma. 2017; 26 (7):652–6. Epub 2017/06/13. https://doi.org/10.1097/IJG.0000000000000700 PMID: 28598960.
8. Sato T, Roy S. Effect of high glucose on fibronectin expression and cell proliferation in trabecular meshwork cells. Investigative ophthalmology & visual science. 2002; 43(1):170–5. Epub 2002/01/05. PMID: 11773028.
9. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Japanese journal of ophthalmology. 2002; 46(3):249–53. Epub 2002/06/14. PMID: 12063033.
10. Min S, Lee T-I, Chung Y, Kim H. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean Journal of Ophthalmology. 2006; 20(3):162–5. https://doi.org/10.3341/kjo.2006.20.3.162 PMID: 17004630.
11. Verma A, Rani PK, Raman R, Pal SS, Laxmi G, Gupta M, et al. Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy. Eye (London, England). 2009; 23(9):1824–30. Epub 2009/08/04. https://doi.org/10.1038/eye.2009.184 PMID: 19648899.

12. Sugimoto M, Sasah M, Ido M, Wakitani Y, Takahashi C, Uji Y. Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica. 2005; 219(6):379–85. Epub 2005/11/16. https://doi.org/10.1159/000083832 PMID: 16286799.

13. Choi JA, Ko SH, Park YR, Jee DH, Ko SH, Park CK. Retinal nerve fiber layer loss is associated with urinary albumin excretion in patients with type 2 diabetes. Ophthalmology. 2015; 122(5):976–81. Epub 2015/02/11. https://doi.org/10.1016/j.ophtha.2015.01.001 PMID: 25668381.

14. Park HY, Kim IT, Park CK. Early diabetic changes in the nerve fibre layer at the macula detected by spectral domain optical coherence tomography. The British journal of ophthalmology. 2011; 95(9):1223–8. Epub 2011/01/11. https://doi.org/10.1136/bjo.2010.191841 PMID: 2126799.

15. Terai N, Spoor E, Haustein M, Hornykewycz K, Haentzsche J, Pillunat LE. Diabetes mellitus affects biomechanical properties of the optic nerve head in the rat. Ophthalmic research. 2012; 47(4):189–94. Epub 2011/12/14. https://doi.org/10.1159/000331990 PMID: 22156545.

16. Amano S, Kaji Y, Oshika T, Oka T, Machinami R, Nagai R, et al. Advanced glycation end products in human optic nerve head. The British journal of ophthalmology. 2001; 85(1):52–5. Epub 2001/01/03. https://doi.org/10.1136/bjo.85.1.52 PMID: 11133712; PubMed Central PMCID: PMCPmc1723673.

17. Diagnosis and classification of diabetes mellitus. Diabetes care. 2004; 27 Suppl 1:S5–s10. Epub 2003/12/25. PMID: 14693921.

18. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(S Suppl):786–806. Epub 1991/05/01. PMID: 2062513.

19. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandemann SE, Kass MA, et al. Classification of non-glaucomatous eyes with type II diabetes. Investigative ophthalmology & visual science. 2016; 57(9):1824–30. Epub 2009/08/04. https://doi.org/10.1038/eye.2009.184 PMID: 19648899.

20. Jung KI, Kang MK, Choi JA, Shin HY, Park CK. Structure-Function Relationship in Glaucoma Patients With Parafoveal Versus Peripheral Nasal Scotoma. Investigative ophthalmology & visual science. 2016; 57(2):420–8. Epub 2016/02/06. https://doi.org/10.1167/iovs.15-18256 PMID: 26848881; PubMed Central PMCID: PMCPmc5110261.

21. Kim YW, Girard MJ, Mani JM, Jeoung JW. Anterior Displacement of Lamina Cribrosa during Valsalva Maneuver in Young Healthy Eyes. PloS one. 2016; 11(7):e0159663. Epub 2016/07/22. https://doi.org/10.1371/journal.pone.0159663 PMID: 27442120; PubMed Central PMCID: PMCPmc4956311.

22. Lee EJ, Kim TW. Lamina Cribrosa Reversal after Trabeculectomy and the Rate of Progressive Retinal Nerve Fiber Layer Thinning. Ophthalmology. 2015; 122(11):2234–42. Epub 2015/08/25. https://doi.org/10.1016/j.ajo.2015.07.020 PMID: 26298719.

23. Lee EJ, Kim TW, Kim M, Kim H. Influence of lamina cribrosa thickness and depth on the rate of progressive retinal nerve fiber layer thinning. Ophthalmology. 2015; 122(4):721–9. Epub 2014/12/01. https://doi.org/10.1016/j.ophtha.2014.10.007 PMID: 25433610.

24. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. American journal of ophthalmology. 2008; 146(4):496–500. Epub 2008/07/22. https://doi.org/10.1016/j.ajo.2008.05.032 PMID: 18639219.

25. Zeiter JH, Shin DH. Diabetes in primary open-angle glaucoma patients with inferior visual field defects. Graefes archive for clinical and experimental ophthalmology – Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1994; 232(4):205–10. Epub 1994/04/01. PMID: 8034207.

26. Zeiter JH, Shin DH, Baek NH. Visual field defects in diabetic patients with primary open-angle glaucoma. American journal of ophthalmology. 1991; 111(5):581–4. Epub 1991/05/15. PMID: 2021166.

27. Jeon SJ, Kwon JW, La TY, Park CK, Choi JA. Characteristics of Retinal Nerve Fiber Layer Defect in Non-glaucomatous Eyes With Type II Diabetes. Investigative ophthalmology & visual science. 2016; 57(10):4008–15. Epub 2016/08/05. https://doi.org/10.1167/iovs.16-19525 PMID: 27493920.

28. Lopes de Faria JM, Russ H, Costa VP. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. The British journal of ophthalmology. 2002; 86(7):725–8. Epub 2002/06/27. PMID: 12084737; PubMed Central PMCID: PMCPmc1771182.
30. Ozdek S, Lonneville YH, Onol M, Yetkin I, Hasanreisoglu BB. Assessment of nerve fiber layer in diabetic patients with scanning laser polarimetry. Eye (London, England). 2002; 16(6):761–5. Epub 2002/11/20. https://doi.org/10.1038/sj.eye.6700207 PMID: 12439673.

31. Park SC, Brumm J, Furlanetto RL, Netto C, Liu Y, Tello C, et al. Lamina cribrosa depth in different stages of glaucoma. Investigative ophthalmology & visual science. 2015; 56(3):2059–64. Epub 2015/02/28. https://doi.org/10.1167/iovs.14-15540 PMID: 25722212.

32. He L, Yang H, Gardiner SK, Williams G, Hardin C, Strouthidis NG, et al. Longitudinal detection of optic nerve head changes by spectral domain optical coherence tomography in early experimental glaucoma. Investigative ophthalmology & visual science. 2014; 55(1):574–86. Epub 2013/11/21. https://doi.org/10.1167/iovs.13-13245 PMID: 24255047; PubMed Central PMCID: PMCPmc3908685.

33. Lee E, Harris A, Sissey B, Schaab T, McIntyre N, Tobe LA, et al. The influence of retinal blood flow on open-angle glaucoma in patients with and without diabetes. European journal of ophthalmology. 2014; 24(4):542–9. Epub 2013/12/25. https://doi.org/10.5301/ejo.5000419 PMID: 24366767.

34. Kim DW, Jeoung JW, Kim YW, Girard MJ, Mari JM, Kim YK, et al. Prelamina and Lamina Cribrosa in Glaucoma Patients With Unilateral Visual Field Loss. Investigative ophthalmology & visual science. 2016; 57(4):1662–70. Epub 2016/04/08. https://doi.org/10.1167/iovs.15-18453 PMID: 27054519.

35. Agoumi Y, Sharpe GP, Hutchison DM, Nicolea MT, Artes PH, Chauhan BC. Laminar and prelaminar tissue displacement during intraocular pressure elevation in glaucoma patients and healthy controls. Ophthalmology. 2011; 118(1):52–9. Epub 2010/07/27. https://doi.org/10.1016/j.ophtha.2010.05.016 PMID: 20656352.

36. Reis AS, O’Leary N, Stanfield MJ, Shuba LM, Nicolea MT, Chauhan BC. Laminar displacement and prelaminar tissue thickness change after glaucoma surgery imaged with optical coherence tomography. Investigative ophthalmology & visual science. 2012; 53(9):5819–26. Epub 2012/07/19. https://doi.org/10.1167/iovs.12-9924 PMID: 22807291.

37. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Investigative ophthalmology & visual science. 1980; 19(2):137–52. Epub 1980/02/01. PMID: 6153173.

38. Ino-Ue M, Zhang L, Naka H, Kuriyama H, Yamamoto M. Polyol metabolism of retrograde axonal transport in diabetic rat large optic nerve fiber. Investigative ophthalmology & visual science. 2000; 41 (13):4055–8. Epub 2000/11/30. PMID: 11095594.

39. Zhang L, Ino-ue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of large- and medium-sized retinal ganglion cells in diabetic rat. Current eye research. 2000; 20(2):131–6. Epub 2000/01/05. PMID: 10617915.

40. Ly A, Yee P, Vessey KA, Phipps JA, Jobling AI, Fletcher EL. Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Investigative ophthalmology & visual science. 2011; 52(13):9316–26. Epub 2011/11/24. https://doi.org/10.1167/iovs.11-7879 PMID: 22110070.

41. Jiang R, Xu L, Liu X, Chen J, Jonas J, Wang Y. Optic nerve head changes after short-term intraocular pressure elevation in acute primary angle-closure suspects. Ophthalmology. 2015; 122(4):730–7. https://doi.org/10.1016/j.ophtha.2014.11.008 PMID: 25556115.

42. Beotra M, Wang X, Tun T, Zhang L, Baskaran M, Aung T, et al. In Vivo Three-Dimensional Lamina Cribrosa Strains in Healthy, Ocular Hypertensive, and Glaucoma Eyes Following Acute Intraocular Pressure Elevation. Investigative ophthalmology & visual science. 2018; 59(1):260–72. https://doi.org/10.1167/iovs.17-21602 PMID: 28877753.

43. Kim C-s, Seong G, Lee N-h, Song K-c. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology. 2011; 118(6):1024–30. https://doi.org/10.1016/j.ophtha.2010.05.016 PMID: 21269703.

44. Li L, Bian A, Cheng G, Zhou Q. Posterior displacement of the lamina cribrosa in normal-tension and high-tension glaucoma. Acta Ophthalmologica. 2016; 94(6):e492–e500. https://doi.org/10.1111/aos.13012 PMID: 27009574.

45. Akkaya S, Kucuk B. Evaluation of the lamina cribrosa in patients with diabetes mellitus using enhanced depth imaging spectral-domain optical coherence tomography. 2018; 15(5):442–8. https://doi.org/10.1177/1479164118782091 PMID: 29895175.

46. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field in normal-tension glaucoma. American journal of ophthalmology. 2002; 134(4):499–512. Epub 2002/10/18. PMID: 12383806.

47. Cheng HC, Guo CY, Chen MJ, Ko YC, Huang N, Liu CJ. Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma. JAMA ophthalmology. 2015; 133(3):269–75. Epub 2014/11/28. https://doi.org/10.1001/jamaophthalmol.2014.4908 PMID: 25429608.
Sawada H, Yoshino T, Fukuchi T, Abe H. Assessment of the vision-specific quality of life using clustered visual field in glaucoma patients. Journal of glaucoma. 2014; 23(2):81–7. Epub 2012/07/26. https://doi.org/10.1097/IJG.0b013e318265bbdc PMID: 22828009.